Frontiers
US$ 22.58
gip vs glp 1 receptor agonist Frontiers Frontiers | The evolution of
Description
$LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes More Info:
With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management
Learn about the benefits of GLP-1 weight loss medications and how they work to support weight management effectively.
Learn screening rules, timing, side effects, and what to ask your clinic before you apply.
